Eli Lilly and Company (NYSE:LLY) Major Shareholder Lilly Endowment Inc Sells 89,458 Shares

Eli Lilly and Company (NYSE:LLYGet Rating) major shareholder Lilly Endowment Inc sold 89,458 shares of the company’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now owns 103,875,441 shares in the company, valued at approximately $34,574,940,536.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Tuesday, July 26th, Lilly Endowment Inc sold 1,601 shares of Eli Lilly and stock. The stock was sold at an average price of $332.52, for a total transaction of $532,364.52.
  • On Friday, July 15th, Lilly Endowment Inc sold 17,310 shares of Eli Lilly and stock. The stock was sold at an average price of $332.76, for a total transaction of $5,760,075.60.
  • On Wednesday, July 6th, Lilly Endowment Inc sold 177,243 shares of Eli Lilly and stock. The stock was sold at an average price of $330.28, for a total value of $58,539,818.04.
  • On Monday, June 27th, Lilly Endowment Inc sold 41,857 shares of Eli Lilly and stock. The shares were sold at an average price of $329.05, for a total value of $13,773,045.85.
  • On Friday, June 24th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly and stock. The stock was sold at an average price of $324.31, for a total value of $69,726,650.00.
  • On Wednesday, June 22nd, Lilly Endowment Inc sold 210,000 shares of Eli Lilly and stock. The stock was sold at an average price of $306.84, for a total transaction of $64,436,400.00.
  • On Friday, May 27th, Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock. The shares were sold at an average price of $318.98, for a total transaction of $63,796,000.00.
  • On Wednesday, May 25th, Lilly Endowment Inc sold 41,610 shares of Eli Lilly and stock. The stock was sold at an average price of $308.95, for a total transaction of $12,855,409.50.
  • On Monday, May 23rd, Lilly Endowment Inc sold 118,856 shares of Eli Lilly and stock. The shares were sold at an average price of $302.73, for a total transaction of $35,981,276.88.
  • On Wednesday, May 18th, Lilly Endowment Inc sold 700 shares of Eli Lilly and stock. The shares were sold at an average price of $302.00, for a total value of $211,400.00.

Eli Lilly and Stock Performance

NYSE:LLY opened at $329.69 on Friday. Eli Lilly and Company has a twelve month low of $220.20 and a twelve month high of $335.33. The company has a market cap of $313.26 billion, a P/E ratio of 48.84, a P/E/G ratio of 2.35 and a beta of 0.37. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 1.60. The company’s 50-day moving average price is $315.84 and its 200-day moving average price is $286.98.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.30. Eli Lilly and had a return on equity of 97.58% and a net margin of 20.90%. The business had revenue of $7.81 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same period in the previous year, the firm posted $1.87 EPS. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 8.31 earnings per share for the current fiscal year.

Eli Lilly and Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 9th. Shareholders of record on Monday, August 15th will be issued a $0.98 dividend. This represents a $3.92 annualized dividend and a yield of 1.19%. The ex-dividend date of this dividend is Friday, August 12th. Eli Lilly and’s payout ratio is currently 58.07%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. The Goldman Sachs Group upped their target price on Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 1st. SVB Leerink assumed coverage on Eli Lilly and in a research note on Monday, May 23rd. They issued an “outperform” rating and a $341.00 target price on the stock. Barclays upped their target price on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, July 7th. Finally, UBS Group upped their target price on Eli Lilly and to $335.00 and gave the stock an “outperform” rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $316.06.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of LLY. Cordant Inc. acquired a new stake in Eli Lilly and during the first quarter worth about $25,000. AllSquare Wealth Management LLC acquired a new stake in shares of Eli Lilly and during the 4th quarter worth approximately $28,000. HWG Holdings LP purchased a new stake in shares of Eli Lilly and during the 4th quarter valued at approximately $28,000. Icapital Wealth LLC acquired a new position in Eli Lilly and in the first quarter valued at approximately $28,000. Finally, Leverty Financial Group LLC purchased a new position in Eli Lilly and in the fourth quarter worth approximately $29,000. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Insider Buying and Selling by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.